GERN
Price
$1.48
Change
-$0.05 (-3.27%)
Updated
Jun 27 closing price
Capitalization
949.01M
39 days until earnings call
UTHR
Price
$284.09
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
12.82B
31 days until earnings call
Interact to see
Advertisement

GERN vs UTHR

Header iconGERN vs UTHR Comparison
Open Charts GERN vs UTHRBanner chart's image
Geron
Price$1.48
Change-$0.05 (-3.27%)
Volume$16.33M
Capitalization949.01M
United Therapeutics
Price$284.09
Change-$0.00 (-0.00%)
Volume$215
Capitalization12.82B
GERN vs UTHR Comparison Chart in %
Loading...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UTHR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GERN vs. UTHR commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GERN is a Buy and UTHR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (GERN: $1.48 vs. UTHR: $284.09)
Brand notoriety: GERN and UTHR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GERN: 155% vs. UTHR: 0%
Market capitalization -- GERN: $949.01M vs. UTHR: $12.82B
GERN [@Biotechnology] is valued at $949.01M. UTHR’s [@Biotechnology] market capitalization is $12.82B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GERN’s FA Score shows that 0 FA rating(s) are green whileUTHR’s FA Score has 0 green FA rating(s).

  • GERN’s FA Score: 0 green, 5 red.
  • UTHR’s FA Score: 0 green, 5 red.
According to our system of comparison, UTHR is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GERN’s TA Score shows that 4 TA indicator(s) are bullish while UTHR’s TA Score has 4 bullish TA indicator(s).

  • GERN’s TA Score: 4 bullish, 3 bearish.
  • UTHR’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, GERN is a better buy in the short-term than UTHR.

Price Growth

GERN (@Biotechnology) experienced а -1.99% price change this week, while UTHR (@Biotechnology) price change was -2.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

GERN is expected to report earnings on Aug 07, 2025.

UTHR is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UTHR($12.8B) has a higher market cap than GERN($949M). UTHR YTD gains are higher at: -19.485 vs. GERN (-58.192). UTHR has higher annual earnings (EBITDA): 1.68B vs. GERN (-114.49M). UTHR has more cash in the bank: 3.32B vs. GERN (397M). GERN has less debt than UTHR: GERN (122M) vs UTHR (200M). UTHR has higher revenues than GERN: UTHR (2.99B) vs GERN (116M).
GERNUTHRGERN / UTHR
Capitalization949M12.8B7%
EBITDA-114.49M1.68B-7%
Gain YTD-58.192-19.485299%
P/E RatioN/A11.32-
Revenue116M2.99B4%
Total Cash397M3.32B12%
Total Debt122M200M61%
FUNDAMENTALS RATINGS
GERN vs UTHR: Fundamental Ratings
GERN
UTHR
OUTLOOK RATING
1..100
2254
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10034
SMR RATING
1..100
9745
PRICE GROWTH RATING
1..100
6581
P/E GROWTH RATING
1..100
7482
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UTHR's Valuation (66) in the Pharmaceuticals Other industry is in the same range as GERN (93) in the Biotechnology industry. This means that UTHR’s stock grew similarly to GERN’s over the last 12 months.

UTHR's Profit vs Risk Rating (34) in the Pharmaceuticals Other industry is significantly better than the same rating for GERN (100) in the Biotechnology industry. This means that UTHR’s stock grew significantly faster than GERN’s over the last 12 months.

UTHR's SMR Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for GERN (97) in the Biotechnology industry. This means that UTHR’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's Price Growth Rating (65) in the Biotechnology industry is in the same range as UTHR (81) in the Pharmaceuticals Other industry. This means that GERN’s stock grew similarly to UTHR’s over the last 12 months.

GERN's P/E Growth Rating (74) in the Biotechnology industry is in the same range as UTHR (82) in the Pharmaceuticals Other industry. This means that GERN’s stock grew similarly to UTHR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GERNUTHR
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
69%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
61%
MACD
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 3 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
56%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 19 days ago
77%
Bearish Trend 4 days ago
60%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
69%
Aroon
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
UTHR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGJMX125.931.87
+1.51%
Fidelity Advisor Communication ServicesI
UPUPX11.410.09
+0.80%
Upright Growth
TESIX25.900.11
+0.43%
Franklin Mutual Shares A
SCAYX11.460.04
+0.35%
Invesco Income Advantage U.S. Fund Y
RLACX24.020.08
+0.33%
Russell Inv US Small Cap Equity A

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-3.27%
SER - GERN
65%
Loosely correlated
+0.65%
DAWN - GERN
39%
Loosely correlated
-0.15%
XNCR - GERN
36%
Loosely correlated
-3.10%
ATXS - GERN
36%
Loosely correlated
N/A
CCCC - GERN
35%
Loosely correlated
-7.89%
More

UTHR and

Correlation & Price change

A.I.dvisor indicates that over the last year, UTHR has been loosely correlated with DAWN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if UTHR jumps, then DAWN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UTHR
1D Price
Change %
UTHR100%
N/A
DAWN - UTHR
38%
Loosely correlated
-0.15%
MNKD - UTHR
38%
Loosely correlated
-0.27%
GERN - UTHR
36%
Loosely correlated
-3.27%
CERO - UTHR
33%
Poorly correlated
-14.66%
UNCY - UTHR
32%
Poorly correlated
+14.48%
More